Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Dechra Pharmaceuticals PLC

DPHAYPNK
Healthcare
Drug Manufacturers - General
$98.00
$1.90(1.98%)
U.S. Market opens in 8h 24m

Dechra Pharmaceuticals PLC (DPHAY) Stock Competitors & Peer Comparison

See (DPHAY) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
DPHAY$98.00+1.98%5.6B-155.56-$0.63N/A
BMYMP$1,002.93+0.29%2T4457.47$0.23+4.11%
RHHBF$483.97-0.62%385.2B23.21$20.85+2.27%
RHHBY$59.18+0.00%382B22.81$2.60+1.45%
RHHVF$477.44+0.00%366.2B22.06$20.85+2.39%
AZNCF$208.62-0.02%323.4B34.60$6.03+1.51%
NVSEF$166.34+3.00%317.4B23.23$7.16+2.39%
GLAXF$31.48+0.02%125.9B16.51$1.89+2.83%
SNYNF$93.97+0.00%115B19.84$4.79+4.64%
CHGCY$30.75+0.00%105.8B37.39$0.86+2.56%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

DPHAY vs BMYMP Comparison February 2026

DPHAY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DPHAY stands at 5.6B. In comparison, BMYMP has a market cap of 2T. Regarding current trading prices, DPHAY is priced at $98.00, while BMYMP trades at $1,002.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DPHAY currently has a P/E ratio of -155.56, whereas BMYMP's P/E ratio is 4457.47. In terms of profitability, DPHAY's ROE is -0.04%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, DPHAY is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for DPHAY.Check BMYMP's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions